In this episode of the SOHO Insider podcast, host Marin Xavier, MD, hematologist and oncologist at Scripps Clinic in San Diego, and Krish Patel, MD, executive director of Hematologic Cancer Research at Sarah Cannon Research Institute, discuss frontline and relapsed management strategies in mantle cell lymphoma.
“In mantle cell lymphoma, disease progression is pretty rapid when patients relapse after a BTK inhibitor, so if I deliver pirtobrutinib, I’m already thinking about what the next step is,” Dr. Patel said.
This episode also covers frontline BTK adoption and managing high-risk or TP53-aberrated disease in younger patients. Plus, an in-depth look into subsequent treatment pathways, including CAR T-cell therapy, bispecific antibody combinations, and options for difficult-to-treat CD20-negative relapses.
Leave feedback about this